Phase 2RecruitingNCT06474598
MTX228 adaptive phase 2 study in T1D
Adaptive phase 2 study of MTX228 in type 1 diabetes; included as a watch-list adjunct/drug-development record.
Primary endpoints
- Change in AUC C-peptide
- Dose selection for phase IIb study
Results so far
No results posted yet.